Vanda Pharmaceuticals (VNDA) Given a $36.00 Price Target at Stifel Nicolaus

Vanda Pharmaceuticals (NASDAQ:VNDA) has been given a $36.00 price target by equities researchers at Stifel Nicolaus in a note issued to investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective suggests a potential upside of 14.39% from the stock’s current price.

VNDA has been the topic of several other reports. Jefferies Financial Group started coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, November 8th. They issued a “buy” rating and a $26.00 target price on the stock. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 7th. ValuEngine raised shares of Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 10th. BidaskClub downgraded shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 1st. Finally, TheStreet raised shares of Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Friday, October 26th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $31.57.

Shares of NASDAQ VNDA opened at $31.47 on Monday. Vanda Pharmaceuticals has a 52 week low of $13.30 and a 52 week high of $33.44. The firm has a market capitalization of $1.31 billion, a P/E ratio of -89.91, a PEG ratio of 3.41 and a beta of 0.86.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. During the same period in the previous year, the firm earned ($0.03) earnings per share. The firm’s revenue for the quarter was up 18.9% on a year-over-year basis. As a group, analysts anticipate that Vanda Pharmaceuticals will post 0.21 EPS for the current year.

A number of institutional investors have recently modified their holdings of VNDA. BlackRock Inc. increased its position in Vanda Pharmaceuticals by 78.3% during the 3rd quarter. BlackRock Inc. now owns 8,845,222 shares of the biopharmaceutical company’s stock valued at $202,999,000 after purchasing an additional 3,884,298 shares during the period. Glenmede Trust Co. NA increased its position in Vanda Pharmaceuticals by 328,291.4% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,766,746 shares of the biopharmaceutical company’s stock valued at $40,545,000 after purchasing an additional 1,766,208 shares during the period. Vanguard Group Inc. increased its position in Vanda Pharmaceuticals by 18.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,969,954 shares of the biopharmaceutical company’s stock valued at $91,111,000 after purchasing an additional 629,086 shares during the period. Wells Fargo & Company MN grew its position in shares of Vanda Pharmaceuticals by 396.9% in the 3rd quarter. Wells Fargo & Company MN now owns 652,305 shares of the biopharmaceutical company’s stock worth $14,971,000 after buying an additional 521,040 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Vanda Pharmaceuticals by 175.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 590,671 shares of the biopharmaceutical company’s stock worth $13,556,000 after buying an additional 376,301 shares during the period. 99.33% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Story: How Do Tariffs Affect Trade Balances?

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit